Northwire Canada EditionSaturday, October 17, 2026
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
Financings

Onco-Innovations arranges $2-million private placement

ONCO · Price

Executive Summary

  • Onco-Innovations Ltd. announced a non-brokered private placement of up to 2,272,727 units at $0.88 per unit, targeting aggregate gross proceeds of up to $2 million.
  • Each unit consists of one common share and one-half of one common share purchase warrant, with warrants exercisable at $1.10 for 36 months.
  • Proceeds are intended for general corporate and working capital purposes, including operational, R&D, and investor relations activities.

Key Details

  • Transaction Structure: Non-brokered private placement of up to 2,272,727 units.
  • Price: $0.88 per unit.
  • Gross Proceeds: Up to $2,000,000.
  • Unit Composition: Each unit comprises one common share and one-half of one common share purchase warrant.
  • Warrant Terms: Each warrant entitles the holder to purchase one share at an exercise price of $1.10 for a period of 36 months.
  • Administrative Fee: The company intends to issue shares equal to 1.0% of the total shares issued in the private placement to an arm's-length third party as an administrative fee for assistance with the placement.
  • Finders' Fees: The company may pay finders' fees and/or issue finders' warrants on the same terms as the investor warrants to eligible parties who introduced subscribers.
  • Use of Proceeds: General corporate and working capital purposes, including pursuit of operational and research and development objectives, and investor relations.
  • Closing Conditions: Subject to regulatory and other necessary approvals.
  • Hold Period: All securities issued are subject to a statutory hold period of four months and one day.

Notable Quotes

  • None provided in the text.
Read the original news release →

More from Onco-Innovations Ltd